Adilya Sabirova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Adilya Sabirova has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Anna Starshinova
Almazov National Medical Research Centre, St. Petersburg 197341, Russia
5 shared publications - Dmitry Anatolievich Kudlay
Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119435 Moscow, Russia
5 shared publications - Raul A. Sharipov
Bashkir State Medical University
4 shared publications - Anastasia Kulpina
Department of Mathematics and Computer Science, Saint Petersburg State University, 199034 Saint Petersburg, Russia
3 shared publications - Artem A. Rubinshtein
Institute of Experimental Medicine, 197376 St. Petersburg, Russia
3 shared publications - Igor Vladimirovich Kudryavtsev
Institute of Experimental Medicine
3 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3693
Machine-Learning-Assisted Risk Stratification for Tuberculosis Infection in High-Risk Groups Receiving Immunosuppressive Therapy
Background: Individuals receiving immunosuppressive therapy, solid-organ transplant recipients, household contacts of patients with tuberculosis, and healthcare workers are at increased risk of Mycobacterium tuberculosis infection and progression to tuberculosis disease. However, currently available immunological tests cannot reliably distinguish tuberculosis infection from active tuberculosis disease or predict individual progression to disease. We aimed to assess the prevalence of immunological evidence of tuberculosis infection across clinically and epidemiologically distinct risk groups and to explore the potential of machine-learning methods for individualised risk stratification. Methods: In this observational study, 544 adults aged 18–75 years were assessed between 2023 and 2026. Participants included patients with pulmonary tuberculosis, tuberculosis-facility healthcare workers, healthcare workers in the general medical network, household and occupational contacts of patients with tuberculosis, patients with rheumatic diseases receiving immunosuppressive therapy, patients undergoing assessment for heart transplantation, heart-transplant recipients, and healthy controls. Participants underwent clinical, epidemiological, radiological, and immunological assessment, including interferon-γ release assays (ELISPOT and QuantiFERON-TB Gold) and the tuberculosis recombinant allergen skin test. Individuals with positive immunological tests underwent additional assessment to exclude active tuberculosis. Exploratory logistic regression and decision-tree models were developed separately for each risk group using demographic and treatment-related variables. Model performance was estimated using repeated stratified 5-fold cross-validation (5 × 10 repeats) with bootstrap optimism correction; discrimination, calibration, sensitivity, specificity, positive and negative predictive values, Cohen’s kappa, and Matthews correlation coefficient were reported with 95% confidence intervals. Results: The prevalence of positive immunological tests was highest among heart-transplant recipients (15 [53.6%] of 28), followed by household contacts (12 [41.4%] of 29), patients undergoing pre-transplant assessment (5 [35.7%] of 14), and tuberculosis-facility healthcare workers (21 [22.6%] of 93). Positivity was lower among patients with rheumatic diseases receiving immunosuppressive therapy (11 [13.9%] of 79) and healthcare workers in the general medical network without documented tuberculosis exposure (7 [10.5%] of 68), and was 3 (4.4%) of 69 among healthy controls. Compared with healthy controls, positivity was significantly higher among tuberculosis-facility healthcare workers, household contacts, patients with rheumatic diseases, and pre-transplant and heart-transplant populations. Exploratory machine-learning analyses were performed separately for the two clinically most relevant immunosuppressed subgroups. In patients with rheumatic diseases (n = 71; 9 positive, 62 negative), pooled ROC AUC was 0.670 (95% CI 0.520–0.824, participant-level bootstrap); age showed 100% bootstrap sign consistency, whereas bDMARD treatment showed 84.6% and sex 55.0%. In the combined heart transplantation group (n = 41; 19 positive, 22 negative), pooled ROC AUC was 0.668 (95% CI 0.522–0.811); tacrolimus and everolimus showed the highest bootstrap sign consistency (100% and 97.6%, respectively); however, because tacrolimus and everolimus are administered predominantly to transplant recipients, these coefficients may partly reflect transplantation status rather than drug-specific effects. Because the heart transplantation group combines pre-transplant candidates and recipients, and because both subgroups had small numbers of events, these associations should be interpreted as exploratory and not as drug-specific causal effects. Conclusions: The prevalence of immunological evidence of tuberculosis infection varied substantially between risk groups and was particularly high among household contacts and heart-transplant recipients. The findings suggest that epidemiological exposure and the type of immunosuppressive therapy should be considered jointly when assessing tuberculosis infection risk. Exploratory machine-learning analyses suggested that treatment-related variables may contribute to individualised risk stratification in the combined heart transplantation group, but the models were developed in small, clinically heterogeneous subgroups and were not externally validated. They should therefore be regarded as hypothesis-generating. Prospective multicentre studies with longitudinal follow-up are required to determine whether integrated clinical, epidemiological, immunological, and treatment-related models can predict incident tuberculosis disease and improve targeted preventive strategies.
- 9 November 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (21) , 3693
Open AccessMachine-Learning-Assisted Risk Stratification for Tuberculosis Infection in High-Risk Groups Receiving Immunosuppressive Therapy
Background: Individuals receiving immunosuppressive therapy, solid-organ transplant recipients, household contacts of patients with tuberculosis, and healthcare workers are at increased risk of Mycobacterium tuberculosis infection and progression to tuberculosis disease. However, currently available immunological tests cannot reliably distinguish tuberculosis infection from active tuberculosis disease or predict individual progression to disease. We aimed to assess the prevalence of immunological evidence of tuberculosis infection across clinically and epidemiologically distinct risk groups and to explore the potential of machine-learning methods for individualised risk stratification. Methods: In this observational study, 544 adults aged 18–75 years were assessed between 2023 and 2026. Participants included patients with pulmonary tuberculosis, tuberculosis-facility healthcare workers, healthcare workers in the general medical network, household and occupational contacts of patients with tuberculosis, patients with rheumatic diseases receiving immunosuppressive therapy, patients undergoing assessment for heart transplantation, heart-transplant recipients, and healthy controls. Participants underwent clinical, epidemiological, radiological, and immunological assessment, including interferon-γ release assays (ELISPOT and QuantiFERON-TB Gold) and the tuberculosis recombinant allergen skin test. Individuals with positive immunological tests underwent additional assessment to exclude active tuberculosis. Exploratory logistic regression and decision-tree models were developed separately for each risk group using demographic and treatment-related variables. Model performance was estimated using repeated stratified 5-fold cross-validation (5 × 10 repeats) with bootstrap optimism correction; discrimination, calibration, sensitivity, specificity, positive and negative predictive values, Cohen’s kappa, and Matthews correlation coefficient were reported with 95% confidence intervals. Results: The prevalence of positive immunological tests was highest among heart-transplant recipients (15 [53.6%] of 28), followed by household contacts (12 [41.4%] of 29), patients undergoing pre-transplant assessment (5 [35.7%] of 14), and tuberculosis-facility healthcare workers (21 [22.6%] of 93). Positivity was lower among patients with rheumatic diseases receiving immunosuppressive therapy (11 [13.9%] of 79) and healthcare workers in the general medical network without documented tuberculosis exposure (7 [10.5%] of 68), and was 3 (4.4%) of 69 among healthy controls. Compared with healthy controls, positivity was significantly higher among tuberculosis-facility healthcare workers, household contacts, patients with rheumatic diseases, and pre-transplant and heart-transplant populations. Exploratory machine-learning analyses were performed separately for the two clinically most relevant immunosuppressed subgroups. In patients with rheumatic diseases (n = 71; 9 positive, 62 negative), pooled ROC AUC was 0.670 (95% CI 0.520–0.824, participant-level bootstrap); age showed 100% bootstrap sign consistency, whereas bDMARD treatment showed 84.6% and sex 55.0%. In the combined heart transplantation group (n = 41; 19 positive, 22 negative), pooled ROC AUC was 0.668 (95% CI 0.522–0.811); tacrolimus and everolimus showed the highest bootstrap sign consistency (100% and 97.6%, respectively); however, because tacrolimus and everolimus are administered predominantly to transplant recipients, these coefficients may partly reflect transplantation status rather than drug-specific effects. Because the heart transplantation group combines pre-transplant candidates and recipients, and because both subgroups had small numbers of events, these associations should be interpreted as exploratory and not as drug-specific causal effects. Conclusions: The prevalence of immunological evidence of tuberculosis infection varied substantially between risk groups and was particularly high among household contacts and heart-transplant recipients. The findings suggest that epidemiological exposure and the type of immunosuppressive therapy should be considered jointly when assessing tuberculosis infection risk. Exploratory machine-learning analyses suggested that treatment-related variables may contribute to individualised risk stratification in the combined heart transplantation group, but the models were developed in small, clinically heterogeneous subgroups and were not externally validated. They should therefore be regarded as hypothesis-generating. Prospective multicentre studies with longitudinal follow-up are required to determine whether integrated clinical, epidemiological, immunological, and treatment-related models can predict incident tuberculosis disease and improve targeted preventive strategies.
- Open Access
- 17 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1883
Detection of Latent Tuberculosis Infection in Patients with Rheumatological Diseases Who Receive Immunosuppressive Therapy
Background/Objectives: Latent tuberculosis infection (LTBI) is a persistent immune response to Mycobacterium tuberculosis antigens in the absence of clinically active tuberculosis. It is now established that progression from LTBI to active tuberculosis is directly associated with immune dysregulation, which frequently occurs in immune-mediated diseases requiring treatment with immunosuppressive agents. The aim of this study was to identify LTBI in patients with rheumatological diseases receiving immunosuppressive therapy using contemporary immunodiagnostic methods. Materials and Methods: A retrospective, prospective, group-control study was conducted, analyzing the results of immunodiagnostics in patients with rheumatological diseases on immunosuppressive therapy and without established contact with tuberculosis patients (n = 44; main group). The control group consisted of healthy individuals (n = 51) with no history of tuberculosis contact, clinical or radiological manifestations of the disease, or signs of chronic pathology exacerbation. Both groups were predominantly female (72.7% in the main group and 62.8% in the control group). The mean age in the patient group was 49.1 years (95% CI [44.77; 53.43]). Rheumatoid arthritis was diagnosed in 29.6% (13) of patients (95% CI [16.06; 43.03]). Articular syndrome was observed in at least 72.7% (32) of patients (95% CI [59.57; 85.89]). In 54.6% (24) of cases (95% CI [39.83; 69.26]), patients received biologic immunosuppressive therapy as basic treatment. In 15.9% (7) of cases (95% CI [5.10; 26.72]), patients received conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Of these, 71.43% (5) (95% CI [35.24; 92.44]) underwent comprehensive examination to exclude active tuberculosis prior to biologic therapy initiation. For immunodiagnostics, all subjects underwent an interferon-gamma release assay (IGRA) and/or testing with a recombinant tuberculosis antigen (ATR) sample, with dynamic assessment of test results. All patients with positive immunodiagnostic results underwent multidetector computed tomography of the chest organs. The level of LTBI in the comparison groups was defined as the percentage of positive immunological test results at a significance level of p < 0.05. Statistical data processing was performed using Microsoft Excel 2019. Results: In the main group, positive immunodiagnostic results were recorded in 20.5% (9) of cases (95% CI [8.54; 32.37]), which is significantly higher than in the control group of healthy individuals (5.8% (3), 95% CI [1.41; 16.54]). This reflects statistically significant differences in immunological test results between groups receiving and not receiving immunosuppressive therapy (χ2 = 4.545, p = 0.034). Dynamic evaluation of the ATR sample revealed positive results in 21.7% (5) of cases (95% CI [4.88; 38.60]), with four out of five patients demonstrating positive conversion. In the third assessment, positivity was observed in 33.33% (5) of cases (95% CI [9.48; 57.19]), which was higher than in the first (χ2 = 1.025, p = 0.312) and second assessments (χ2 = 0.629, p = 0.428), although these differences were not statistically significant. Notably, in two out of five patients, the ATR test result changed from negative to positive. Conclusions: In patients with rheumatological diseases receiving immunosuppressive therapy, LTBI was detected in 20.5%, which is significantly higher than in healthy individuals (5.8%, p = 0.034). Furthermore, there was an increase in the proportion of positive tests over time (up to 21.7% and 33.3% on immunotherapy), suggesting an increasing risk of progression to active tuberculosis infection.
- 17 June 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (12) , 1883
Open AccessDetection of Latent Tuberculosis Infection in Patients with Rheumatological Diseases Who Receive Immunosuppressive Therapy
Background/Objectives: Latent tuberculosis infection (LTBI) is a persistent immune response to Mycobacterium tuberculosis antigens in the absence of clinically active tuberculosis. It is now established that progression from LTBI to active tuberculosis is directly associated with immune dysregulation, which frequently occurs in immune-mediated diseases requiring treatment with immunosuppressive agents. The aim of this study was to identify LTBI in patients with rheumatological diseases receiving immunosuppressive therapy using contemporary immunodiagnostic methods. Materials and Methods: A retrospective, prospective, group-control study was conducted, analyzing the results of immunodiagnostics in patients with rheumatological diseases on immunosuppressive therapy and without established contact with tuberculosis patients (n = 44; main group). The control group consisted of healthy individuals (n = 51) with no history of tuberculosis contact, clinical or radiological manifestations of the disease, or signs of chronic pathology exacerbation. Both groups were predominantly female (72.7% in the main group and 62.8% in the control group). The mean age in the patient group was 49.1 years (95% CI [44.77; 53.43]). Rheumatoid arthritis was diagnosed in 29.6% (13) of patients (95% CI [16.06; 43.03]). Articular syndrome was observed in at least 72.7% (32) of patients (95% CI [59.57; 85.89]). In 54.6% (24) of cases (95% CI [39.83; 69.26]), patients received biologic immunosuppressive therapy as basic treatment. In 15.9% (7) of cases (95% CI [5.10; 26.72]), patients received conventional synthetic disease-modifying antirheumatic drugs (DMARDs). Of these, 71.43% (5) (95% CI [35.24; 92.44]) underwent comprehensive examination to exclude active tuberculosis prior to biologic therapy initiation. For immunodiagnostics, all subjects underwent an interferon-gamma release assay (IGRA) and/or testing with a recombinant tuberculosis antigen (ATR) sample, with dynamic assessment of test results. All patients with positive immunodiagnostic results underwent multidetector computed tomography of the chest organs. The level of LTBI in the comparison groups was defined as the percentage of positive immunological test results at a significance level of p < 0.05. Statistical data processing was performed using Microsoft Excel 2019. Results: In the main group, positive immunodiagnostic results were recorded in 20.5% (9) of cases (95% CI [8.54; 32.37]), which is significantly higher than in the control group of healthy individuals (5.8% (3), 95% CI [1.41; 16.54]). This reflects statistically significant differences in immunological test results between groups receiving and not receiving immunosuppressive therapy (χ2 = 4.545, p = 0.034). Dynamic evaluation of the ATR sample revealed positive results in 21.7% (5) of cases (95% CI [4.88; 38.60]), with four out of five patients demonstrating positive conversion. In the third assessment, positivity was observed in 33.33% (5) of cases (95% CI [9.48; 57.19]), which was higher than in the first (χ2 = 1.025, p = 0.312) and second assessments (χ2 = 0.629, p = 0.428), although these differences were not statistically significant. Notably, in two out of five patients, the ATR test result changed from negative to positive. Conclusions: In patients with rheumatological diseases receiving immunosuppressive therapy, LTBI was detected in 20.5%, which is significantly higher than in healthy individuals (5.8%, p = 0.034). Furthermore, there was an increase in the proportion of positive tests over time (up to 21.7% and 33.3% on immunotherapy), suggesting an increasing risk of progression to active tuberculosis infection.
- Open Access
- 11 June 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (6) , 1313
Immunological Mechanisms and Machine Learning Applications in Post-COVID-19 Syndrome: A Narrative Review
Post-COVID-19 syndrome (PCS), also referred to as post-acute sequelae of SARS-CoV-2 infection (PASC), represents a heterogeneous set of persistent clinical manifestations developing after acute infection. These conditions are associated with immune dysregulation, autonomic imbalance, impaired thymic function, and possible viral persistence. Objective: This study aims to systematically synthesise current evidence on the immunopathogenesis of PCS and to critically evaluate the application of artificial intelligence (AI) and machine learning (ML) approaches for its prediction and clinical stratification. Methods: A PRISMA 2020–informed systematic review was conducted using PubMed/MEDLINE, Scopus, Web of Science, elibrary.ru and Embase databases (January 2020–December 2025). Studies addressing immunopathological mechanisms and AI/ML applications in PCS were selected based on predefined eligibility criteria. Risk of bias in prediction studies was assessed using the PROBAST tool. Due to heterogeneity, a structured qualitative synthesis was performed. Current evidence indicates that PCS may result from sustained systemic inflammation, cytokine dysregulation, autoimmunity, and delayed restoration of T-cell homeostasis, including reduced thymic output of naïve T lymphocytes. Persistent thymic dysfunction may contribute to prolonged immune imbalance, increased susceptibility to secondary infections, and reactivation of latent viruses. AI/ML approaches—including gradient boosting, ensemble learning, deep neural networks, and natural language processing—have demonstrated promising performance across multimodal datasets. However, significant limitations were identified, including small sample sizes, overfitting, lack of external validation, and heterogeneity in outcome definitions. Conclusions: The integration of immunopathological insights with data-driven modelling highlights the potential of combined approaches for improving PCS risk stratification. However, current AI models remain insufficiently validated for clinical implementation. Future research should prioritise methodological standardisation, external validation, and incorporation of mechanistically informed biomarkers.
- 11 June 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (6) , 1313
Open AccessImmunological Mechanisms and Machine Learning Applications in Post-COVID-19 Syndrome: A Narrative Review
Post-COVID-19 syndrome (PCS), also referred to as post-acute sequelae of SARS-CoV-2 infection (PASC), represents a heterogeneous set of persistent clinical manifestations developing after acute infection. These conditions are associated with immune dysregulation, autonomic imbalance, impaired thymic function, and possible viral persistence. Objective: This study aims to systematically synthesise current evidence on the immunopathogenesis of PCS and to critically evaluate the application of artificial intelligence (AI) and machine learning (ML) approaches for its prediction and clinical stratification. Methods: A PRISMA 2020–informed systematic review was conducted using PubMed/MEDLINE, Scopus, Web of Science, elibrary.ru and Embase databases (January 2020–December 2025). Studies addressing immunopathological mechanisms and AI/ML applications in PCS were selected based on predefined eligibility criteria. Risk of bias in prediction studies was assessed using the PROBAST tool. Due to heterogeneity, a structured qualitative synthesis was performed. Current evidence indicates that PCS may result from sustained systemic inflammation, cytokine dysregulation, autoimmunity, and delayed restoration of T-cell homeostasis, including reduced thymic output of naïve T lymphocytes. Persistent thymic dysfunction may contribute to prolonged immune imbalance, increased susceptibility to secondary infections, and reactivation of latent viruses. AI/ML approaches—including gradient boosting, ensemble learning, deep neural networks, and natural language processing—have demonstrated promising performance across multimodal datasets. However, significant limitations were identified, including small sample sizes, overfitting, lack of external validation, and heterogeneity in outcome definitions. Conclusions: The integration of immunopathological insights with data-driven modelling highlights the potential of combined approaches for improving PCS risk stratification. However, current AI models remain insufficiently validated for clinical implementation. Future research should prioritise methodological standardisation, external validation, and incorporation of mechanistically informed biomarkers.
- Open Access
Detection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods
Background/Objectives: Latent tuberculosis infection (LTBI) represents a critical reservoir for subsequent development of active tuberculosis (ATB) and poses significant challenges for early diagnosis and disease prevention. Traditional immunological assays, such as interferon-gamma release assays (IGRAs), are limited in their ability to reliably distinguish LTBI from ATB. Recent advances in high-throughput omics technologies and machine learning (ML) approaches offer new opportunities for precise, biomarker-based differential diagnostics. Methods: Transcriptomic and proteomic profiling of host immune responses has revealed reproducible gene and protein signatures associated with LTBI and ATB. The integration of ML techniques—including feature selection, dimensionality reduction, multimodal learning, and explainable AI—facilitates the construction of robust diagnostic models. Single-modality signatures, derived from RNA-seq, microarrays, or proteomic assays, are complemented by multimodal approaches that incorporate soluble mediators, immunological readouts, and imaging-derived features. Deep learning frameworks, such as convolutional neural networks and transformer-based architectures, enhance the extraction of complex molecular and structural patterns from high-dimensional datasets. Results: ML-driven analyses of transcriptomic and proteomic data consistently outperform conventional immunological tests in terms of sensitivity, specificity, and clinical applicability. Multimodal integration further improves diagnostic accuracy and robustness. These advances support the translational development of concise, quantitative reverse transcription PCR (qRT-PCR)-based biomarker panels suitable for routine clinical application, enabling early and reliable differentiation between LTBI and ATB. Overall, the combination of high-throughput omics and AI-based analytical frameworks provides a promising pathway for enhancing global tuberculosis diagnostics. Conclusions: This review provides a structured and critical synthesis of transcriptomic and proteomic biomarker research for LTBI and ATB discrimination, with a particular emphasis on machine learning–based analytical frameworks. Unlike previous narrative reviews, we systematically compare data-generating platforms, modelling strategies, validation approaches, and sources of heterogeneity across studies. We further identify key translational barriers, including cohort homogeneity, platform dependency, and limited external validation, and propose directions for future research aimed at improving clinical applicability.
Open AccessDetection for New Biomarkers of Tuberculosis Infection Activity Using Machine Learning Methods
Background/Objectives: Latent tuberculosis infection (LTBI) represents a critical reservoir for subsequent development of active tuberculosis (ATB) and poses significant challenges for early diagnosis and disease prevention. Traditional immunological assays, such as interferon-gamma release assays (IGRAs), are limited in their ability to reliably distinguish LTBI from ATB. Recent advances in high-throughput omics technologies and machine learning (ML) approaches offer new opportunities for precise, biomarker-based differential diagnostics. Methods: Transcriptomic and proteomic profiling of host immune responses has revealed reproducible gene and protein signatures associated with LTBI and ATB. The integration of ML techniques—including feature selection, dimensionality reduction, multimodal learning, and explainable AI—facilitates the construction of robust diagnostic models. Single-modality signatures, derived from RNA-seq, microarrays, or proteomic assays, are complemented by multimodal approaches that incorporate soluble mediators, immunological readouts, and imaging-derived features. Deep learning frameworks, such as convolutional neural networks and transformer-based architectures, enhance the extraction of complex molecular and structural patterns from high-dimensional datasets. Results: ML-driven analyses of transcriptomic and proteomic data consistently outperform conventional immunological tests in terms of sensitivity, specificity, and clinical applicability. Multimodal integration further improves diagnostic accuracy and robustness. These advances support the translational development of concise, quantitative reverse transcription PCR (qRT-PCR)-based biomarker panels suitable for routine clinical application, enabling early and reliable differentiation between LTBI and ATB. Overall, the combination of high-throughput omics and AI-based analytical frameworks provides a promising pathway for enhancing global tuberculosis diagnostics. Conclusions: This review provides a structured and critical synthesis of transcriptomic and proteomic biomarker research for LTBI and ATB discrimination, with a particular emphasis on machine learning–based analytical frameworks. Unlike previous narrative reviews, we systematically compare data-generating platforms, modelling strategies, validation approaches, and sources of heterogeneity across studies. We further identify key translational barriers, including cohort homogeneity, platform dependency, and limited external validation, and propose directions for future research aimed at improving clinical applicability.
- Open Access
Alterations in the Immune Response in Individuals with Latent Tuberculosis Infection
Latent tuberculosis infection (LTBI) represents a biologically active yet clinically asymptomatic stage of Mycobacterium tuberculosis (Mtb) persistence. This condition is characterized by subtle immunometabolic alterations reflecting the host–pathogen equilibrium. Understanding the mechanisms and biomarkers associated with the preclinical phase of LTBI is crucial for preventing progression to active tuberculosis (ATB). Recent advances have identified multiple immunological, transcriptomic, metabolic, and imaging-based approaches that enable stratification of individuals at increased risk of LTBI reactivation. Quantitative assays such as IGRA, multiplex and T-cell activation marker (TAM) tests, as well as interferon-related transcriptional signatures, demonstrate predictive potential when combined with functional assays (MGIA) and metabolic imaging (PET/CT). Experimental primate models faithfully reproduce the spectrum from latency to reactivation, allowing for validation of biomarkers and vaccine or immunomodulatory strategies. The review also highlights the particular challenges of multidrug-resistant LTBI (MDR-LTBI), where standard chemoprophylaxis is less effective and immune control plays a decisive role. The preclinical phase of LTBI constitutes a key point in the TB control cascade. Integrating immunological, transcriptomic, and radiological data into risk-based screening algorithms could substantially improve early detection and targeted prevention. Translating research-derived signatures into clinically applicable, standardized, and cost-effective diagnostic tools requires coordinated international efforts, technological transfer, and policy-level support to reduce TB reactivation and transmission, including MDR-TB.
Open AccessAlterations in the Immune Response in Individuals with Latent Tuberculosis Infection
Latent tuberculosis infection (LTBI) represents a biologically active yet clinically asymptomatic stage of Mycobacterium tuberculosis (Mtb) persistence. This condition is characterized by subtle immunometabolic alterations reflecting the host–pathogen equilibrium. Understanding the mechanisms and biomarkers associated with the preclinical phase of LTBI is crucial for preventing progression to active tuberculosis (ATB). Recent advances have identified multiple immunological, transcriptomic, metabolic, and imaging-based approaches that enable stratification of individuals at increased risk of LTBI reactivation. Quantitative assays such as IGRA, multiplex and T-cell activation marker (TAM) tests, as well as interferon-related transcriptional signatures, demonstrate predictive potential when combined with functional assays (MGIA) and metabolic imaging (PET/CT). Experimental primate models faithfully reproduce the spectrum from latency to reactivation, allowing for validation of biomarkers and vaccine or immunomodulatory strategies. The review also highlights the particular challenges of multidrug-resistant LTBI (MDR-LTBI), where standard chemoprophylaxis is less effective and immune control plays a decisive role. The preclinical phase of LTBI constitutes a key point in the TB control cascade. Integrating immunological, transcriptomic, and radiological data into risk-based screening algorithms could substantially improve early detection and targeted prevention. Translating research-derived signatures into clinically applicable, standardized, and cost-effective diagnostic tools requires coordinated international efforts, technological transfer, and policy-level support to reduce TB reactivation and transmission, including MDR-TB.